CCO Treatment Updates

Anthracyclines in the Treatment of Multiple Myeloma: Traditional and Evolving Roles

Module

Anthracyclines in the Treatment of Multiple Myeloma: Traditional and Evolving Roles

Faculty:
Mohamad A. Hussein, MD

CME CREDIT INFORMATION

Release Date: 09/06/07

Expiration Date: 09/05/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Mohamad A. Hussein, MD, discusses the integration of anthracyclines into existing combination therapies and the emergence of novel anthracycline-containing combination regimens for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the different clinical attributes of anthracyclines including doxorubicin and pegylated liposomal doxorubicin
Explain the rationale behind combining pegylated liposomal doxorubicin and immunomodulatory agents
Summarize the clinical data on the use of pegylated liposomal doxorubicin with other agents, such as proteasome inhibitors

Interactive Case Challenges

Anthracycline Therapy in a 55-Year-Old Man With Relapsed Multiple Myeloma

Faculty:
Nikhil Munshi, MD

CME CREDIT INFORMATION

Release Date: 09/18/07

Expiration Date: 09/17/08

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Along with Nikhil Munshi, MD, consider options for treating de novo and recurrent multiple myeloma in a male patient who is otherwise healthy and has poor risk cytogenetics.

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify appropriate treatment options for first-line therapy of multiple myeloma in a young patient who is otherwise healthy
Discuss management strategies for hypercalcemia of malignancy
Describe second-line treatment options for a patient with poor cytogenetics

Anthracycline Therapy in a 67-Year-Old Man With Multiple Myeloma Who Has Relapsed After ASCT

Faculty:
Seema Singhal, MD

CME CREDIT INFORMATION

Release Date: 09/27/07

Expiration Date: 09/26/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Join Seema Singhal, MD, in an exploration of the treatment options for a patient with multiple myeloma who has relapsed after 1 autologous stem cell transplantation.

Learning Objectives

Upon completion of this activity, participants should be able to:

Review treatment options for a patient with multiple myeloma who has relapsed after autologous stem cell transplantation
Discuss the management of bortezomib treatment–related neuropathy
Describe an appropriate course of action for a patient who experiences a minor relapse following complete response while receiving bortezomib plus pegylated liposomal doxorubicin therapy

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.